Low-cost ultra-wide genotyping using roche/454 pyrosequencing for surveillance of HIV drug resistance

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Dudley, Dawn M ^a   Chin, Emily N ^b   Bimber, Benjamin N ^a   Sanabani, Sabri S ^d   Tarosso, Leandro F ^d   Costa, Priscilla R ^d   Sauer, Mariana M ^d   Kallas, Esper G ^d   O'Connor, David H ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE; VIRUS RNA;

ADULT; ANALYTICAL EQUIPMENT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD ANALYSIS; BRAZIL; COHORT ANALYSIS; COST CONTROL; DRUG MONITORING; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PYROSEQUENCING; SEQUENCE ANALYSIS; BLOOD; DRUG EFFECT; ECONOMICS; FEASIBILITY STUDY; GENETICS; GENOTYPING TECHNIQUE; MUTATION; POLYMERASE CHAIN REACTION;

DRUG RESISTANCE, VIRAL; FEASIBILITY STUDIES; GENOTYPING TECHNIQUES; HIV; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, RNA;

EID: 84860521943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036494     Document Type: Article

References (31)

1. WHO UNICEF, UNAIDS, (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. 15 Available: http://www.who.int/hiv/pub/2010progressreport/en/. Accessed 2012 Apr.
2. Ndembi N, Hamers RL, Sigaloff KC, Lyagoba F, Magambo B, et al. (2011) Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 25: 905-910.
3. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 27: 5-12.
4. Sungkanuparph S, Sukasem C, Kiertiburanakul S, Pasomsub E, Chantratita W, (2012) Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int AIDS Soc 15: 12.
5. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF, (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13 (Suppl 2): 25-36.
6. World Health Organization (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a public health approach. Geneva WHO.
7. Kallas EG, Bassichetto KC, Oliveira SM, Goldenberg I, Bortoloto R, et al. (2004) Establishment of the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) strategy in the city of Sao Paulo, Brazil. Braz J Infect Dis 8: 399-406.
8. Sanabani SS, Pastena ER, da Costa AC, Martinez VP, Kleine-Neto W, et al. (2011) Characterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in Sao Paulo, Brazil. PLoS One 6: e25869.
9. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079.
10. Stajich JE, Block D, Boulez K, Brenner SE, Chervitz SA, et al. (2002) The Bioperl toolkit: Perl modules for the life sciences. Genome Res 12: 1611-1618.
11. Li H, Durbin R, (2010) Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595.
12. Gonsalez CR, Alcalde R, Nishiya A, Barreto CC, Silva FE, et al. (2007) Drug resistance among chronic HIV-1-infected patients naive for use of anti-retroviral therapy in Sao Paulo city. Virus Res 129: 87-90.
13. Ferreira FG, Pinto JA, Kakehasi FM, Cleto S, Tupinambas U, et al. (2010) Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically Infected children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses 26: 229-232.
14. Pedroso C, Queiroz AT, Alcantara LC, Drexler JF, Diaz RS, et al. (2007) High prevalence of primary antiretroviral resistance among HIV-1-infected adults and children in Bahia, a northeast state of Brazil. J Acquir Immune Defic Syndr 45 (2): 251-253.
15. Eshleman SH, Hackett JJ, Swanson P, Cunningham SP, Drews B, et al. (2004) Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol 42: 2711-2717.
16. WHO UNAIDS, UNICEF, (2009) Towards universal access: scaling up HIV interventions in the health sector. Progress report, September 55. 15 Available: http://www.who.int/hiv/pub/2009progressreport/en/. Accessed 2012 Apr.
17. Ji H, Li Y, Graham M, Liang BB, Pilon R, et al. (2011) Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance. Antivir Ther 16: 871-878.
18. World Health Organization (2010) WHO/HIVResNet HIV Drug Resistance Laboratory Strategy. 15 Available: http://www.who.int/hiv/pub/drugresistance/hiv_reslab_strategy.pdf. Accessed 2012 Apr.
19. Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, et al. (2011) Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure. PLoS One 6: e21655.
20. Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, et al. (2009) Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 52: 309-315.
21. Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, et al. (2010) Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One 5: e10992.
22. Ji H, Masse N, Tyler S, Liang B, Li Y, et al. (2010) HIV drug resistance surveillance using pooled pyrosequencing. PLoS One 5: e9263.
23. Bebenek K, Abbotts J, Roberts JD, Wilson SH, Kunkel TA, (1989) Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J Biol Chem 264: 16948-16956.
24. Wainberg MA, Zaharatos GJ, Brenner BG, (2011) Development of antiretroviral drug resistance. N Engl J Med 365: 637-646.
25. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406-413.
26. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
27. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, et al. (2009) Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients. Clin Infect Dis 48: 239-247.
28. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, et al. (2008) Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 22: 1417-1423.
29. De Wolf H, Van Marck H, Mostmans W, Thys K, Vandenbroucke I, et al. (2011) HIV-1 nucleotide mixture detection in the virco((R))TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing. J Virol Methods 175: 129-132.
30. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, et al. (2011) Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One 6: e28952.
31. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, et al. (2012) Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26: 185-192.